PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AbbVie submits Rinvoq for ankylosing spondylitis

AbbVie has filed for approval of Rinvoq (upadacitinib) in the US to treat adult patients with active ankylosing spondylitis.

Ankylosing spondylitis is a chronic, progressive, inflammatory musculoskeletal disease impacting more than five million people worldwide, with a range of symptoms posing significant physical, psychological and economic burden on affected individuals.

The application is supported by data from SELECT-AXIS 1, in which the JAK inhibitor demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis, with twice as many patients (52%) achieving an (ASAS) 40 response versus placebo (26%).

“Ankylosing spondylitis is a debilitating disease that can cause severe pain, restricted mobility and lasting structural damage. With limited treatment options, innovation is crucial to help more patients living with active ankylosing spondylitis reach their treatment goals,” said Michael Severino, vice chairman and president, AbbVie.

“Rinvoq has the potential to improve care by helping to provide disease control, addressing pain and improving function.”

A regulatory application was also submitted to the EMA for the treatment of adult patients with active ankylosing spondylitis earlier this year, the firm noted.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026